Efficacy of Conversion From Bedtime NPH Insulin Injection to Once- or Twice-Daily Injections of Insulin Glargine in Type 1 Diabetic Patients Using Basal/Bolus Therapy
Open accessAbstract
Relationship between vascular endothelial growth factor and
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The pharmacokinetic and pharmacodynamic limitations of currently available basal insulins can necessitate more frequent dosing in clinical practice to maintain adequate blood glucose control.
“Subsequently, the pharmacokinetic and pharmacodynamic limitations can necessitate more frequent dosing of basal insulin in clinical practice to maintain adequate blood glucose control [4–6]”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [4]
Cites
Raskin, P., Klaff, L., Bergenstal, R., Hallé, J. P., Donley, D., & Mecca, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1666 · Cited by 250 · see citing works
Pieber, T. R., Eugène-Jolchine, I., & Derobert, E. (2000) · Diabetes Care · doi:10.2337/diacare.23.2.157 · Cited by 224 · see citing works
Rosenstock, J., Park, G., Zimmerman, J., & U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1137 · Cited by 196 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Hirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667 · see citing works
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248 · see citing works
Heise, T., & Pieber, T. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00756.x · Cited by 236 · see citing works
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226 · see citing works
“quent dosing of basal insulin in clinical practice to maintain adequate blood glucose control [4–6] and mandate that both IGlar and IDet are administered at the same”
MethodHirsch, I. B., Bode, B. W., Garg, S. K., Lane, W. S., Sussman, A., Hu, P., Santiago, O. M., Kolaczynski, J. W., & for the Insulin Aspart CSII/MDI Comparison Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.3.533 · Cited by 196 · see citing works
Hollander, P. A., Cooper, J., Bregnhøj, J. F., & Pedersen, C. B. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.001 · Cited by 161 · see citing works
Heise, T., Hövelmann, U., Nosek, L., Hermanski, L., Bøttcher, S. G., & Haahr, H. L. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1058779 · Cited by 152 · see citing works
Liebl, A., Prager, R., Binz, K., Kaiser, M., Bergenstal, R. M., Gallwitz, B., & PREFER Study Group (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00915.x · Cited by 147 · see citing works
Complementary Therapies for Diabetes: The Case for Chromium, Magnesium, and Antioxidants
Guerrero‐Romero, F., & Rodríguez‐Morán, M. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.004 · Cited by 147 · see citing works
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
Swinnen, S. G. H. A., Simon, A. C. R., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006383.pub2 · Cited by 137 · see citing works
Pieber, T. R., Treichel, H., Hompesch, B., Philotheou, A., Mordhorst, L., Gall, M., & Robertson, L. I. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02113.x · Cited by 125 · see citing works
Heise, T., & Mathieu, C. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12782 · Cited by 106 · see citing works
Heller, S. R., Koenen, C., & Bode, B. W. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.006 · Cited by 94 · see citing works
Cengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Ehtisham, S., Fairchild, J. M., Jarosz-Chobot, P. A., Ng, S. M., Paterson, M. A., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13442 · Cited by 98 · see citing works
Refining basal insulin therapy: what have we learned in the age of analogues?
DeVries, J. H., Nattrass, M., & Pieber, T. R. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.762 · Cited by 94 · see citing works
Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89 · see citing works
Chapman, T. M., & Perry, C. M. (2004) · Drugs · doi:10.2165/00003495-200464220-00008 · Cited by 91 · see citing works
Clinical use of insulin degludec
Vora, J. P., Cariou, B., Evans, M., Gross, J. L., Harris, S. B., Landstedt‐Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.002 · Cited by 73 · see citing works
Robbins, D. C., Beisswenger, P. J., Ceriello, A., Goldberg, R. B., Moses, R. G., Pagkalos, E., Miličević, Z., Jones, C. A., Sarwat, S., & Tan, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.016 · Cited by 65 · see citing works
Intermediate acting versus long acting insulin for type 1 diabetes mellitus
Vardi, M., Jacobson, E., Nini, A., & Bitterman, H. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006297.pub2 · Cited by 53 · see citing works
Circadian Variation in Efficacy of Medications
Walton, J. C., Walker, W. H., Bumgarner, J. R., Meléndez‐Fernández, O. H., Liu, J. A., Hughes, H. L., Kaper, A. L., & Nelson, R. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2073 · Cited by 51 · see citing works
Insulin Glargine: a review 8 years after its introduction
Goykhman, S., Drincic, A., Desmangles, J., & Rendell, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902775677 · Cited by 49 · see citing works
Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study
IMBERGAMO, M., AMATO, M., SCIORTINO, G., GAMBINA, M., ACCIDENTI, M., CRISCIMANNA, A., GIORDANO, C., & GALLUZZO, A. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.013 · Cited by 46 · see citing works
The Future of Basal Insulin Supplementation
Simon, A. C. R., & DeVries, J. H. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0251 · Cited by 46 · see citing works
Floch, J. P. L., Lévy, M., Mosnier-Pudar, H., Nobels, F. R. E., Laroche, S., Gonbert, S., Eschwège, É., Fontaine, P., & The Assessment of Detemir Administration in a Progressive Treat-to-Target Trial (ADAPT) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0332 · Cited by 44 · see citing works
Thomas, R. M., Aldibbiat, A. M., Griffin, W., Cox, M. A. A., Leech, N., & Shaw, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02196.x · Cited by 40 · see citing works
Evans, M., Wolden, M. L., Gundgaard, J., Chubb, B., & Christensen, T. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.971160 · Cited by 38 · see citing works
Goldman, J. D., Kapitza, C., Pettus, J., & Heise, T. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335192 · Cited by 38 · see citing works
Clinical Experience with Insulin Glargine in Type 1 Diabetes
Garg, S. K., Moser, E. G., Dain, M., & Rodionova, A. S. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0135 · Cited by 35 · see citing works
Evans, M., Chubb, B., & Gundgaard, J. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0236-9 · Cited by 33 · see citing works
New Insulin Analogues and Routes of Delivery
Roach, P. J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847090-00003 · Cited by 31 · see citing works
Kusunoki, Y., Katsuno, T., Miyakoshi, K., Ikawa, T., Nakae, R., Ochi, F., Tokuda, M., Akagami, T., Murai, K., Miuchi, M., et al. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0048-5 · Cited by 28 · see citing works
An Update on the Long‐Acting Insulin Analogue Glargine
Horsdal, H. T., Johnsen, S. P., & Rungby, J. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_352.x · Cited by 27 · see citing works
Insulin Therapy in Diabetes Mellitus
Bell, D. S. H. (2007) · Drugs · doi:10.2165/00003495-200767130-00002 · Cited by 26 · see citing works
Self-citationSharplin, P., Gordon, J. P., Peters, J. R., Tetlow, A., Longman, A. J., & McEwan, P. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-9 · Cited by 25 · see citing works
Sharplin, P., Gordon, J. P., Peters, J. R., Tetlow, A., Longman, A. J., & McEwan, P. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-3 · Cited by 24 · see citing works
Injectable systems for long-lasting insulin therapy
Niloy, K. K., & Lowe, T. L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115121 · Cited by 22 · see citing works
Bryant, G. A., McDanel, D. L., Horner, K. E., Farris, K. B., & Newkirk, E. N. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1168 · Cited by 21 · see citing works
Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus
Chatterjee, S., Tringham, J. R., & Davies, M. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.10.1357 · Cited by 19 · see citing works
Pollock, R. F., & Tikkanen, C. K. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1245663 · Cited by 17 · see citing works
Lefever, E., Vliebergh, J., & Mathieu, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1856813 · Cited by 16 · see citing works
Insulin degludec in J apanese patients with type 1 diabetes mellitus: A randomized controlled trial
Iwamoto, Y., Clauson, P., Nishida, T., & Kaku, K. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00240.x · Cited by 14 · see citing works
Meneghini, L., & Sparrow-Bodenmiller, J. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0184 · Cited by 13 · see citing works
Basal-Prandial Insulin Therapy: Scientific Concept Review and Application
Leahy, J. L. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200607000-00005 · Cited by 13 · see citing works
Johansen, O. E. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3884 · Cited by 13 · see citing works
Tosaka, Y., Kanazawa, A., Ikeda, F., Iida, M., Sato, J., Matsumoto, K., Uchida, T., Tamura, Y., Ogihara, T., Mita, T., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/176261 · Cited by 12 · see citing works
Detemir as a once-daily basal insulin in type 2 diabetes
Nelson (2011) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s19539 · Cited by 11 · see citing works
Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing
Fox, M. A., Perry, M., & Liu‐DeRyke, X. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2373 · Cited by 11 · see citing works
Current usage of long-acting insulin analogs in patients with type 2 diabetes mellitus
Aktaş, G., & Duman, T. T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2320631 · Cited by 10 · see citing works
KANAZAWA, Y., Igarashi, Y., Komiya, K., Sakurai, Y., Shimizu, T., Fujitani, Y., Tanaka, Y., Watada, H., Kawamori, R., & Hirose, T. (2007) · Endocrine Journal · doi:10.1507/endocrj.k07e-035 · Cited by 10 · see citing works
Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
Eledrisi, M. S., Suleiman, N., Salameh, O., Hamad, M. K., Rabadi, O., Mohamed, A. S., Adawi, R. M. A., & Salam, A. (2018) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2018.12.002 · Cited by 8 · see citing works
Mathieu, C., Weisnagel, S. J., Stella, P., Bruhwyler, J., & Alexandre, K. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00749-1 · Cited by 6 · see citing works
Erickson, T. N., Devine, E. B., O’Young, T. S., Hanson, L. J., French, B. C., & Brennan, C. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050439 · Cited by 6 · see citing works
Housel, A. K., Shaw, R. F., & Waterbury, N. V. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.01.020 · Cited by 5 · see citing works
Urakami, T., Kuwabara, R., Habu, M., Komiya, K., Nagano, N., Suzuki, J., & Mugishima, H. (2012) · Diabetology International · doi:10.1007/s13340-011-0063-6 · Cited by 5 · see citing works
Comparing Insulins Detemir and Glargine in Type 2 Diabetes: More Similarities than Differences
Reynolds, L. R. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2116 · Cited by 5 · see citing works
Puppalwar, G., Sawant, S., Silgiri, B., Shukla, K., & Barkate, H. V. (2017) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2017.74011 · Cited by 4 · see citing works
Burge, M. R., Schroeder, E. R., & Mitchell, S. (2012) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2012.22032 · Cited by 4 · see citing works
Bell, D. S. H. (2007) · Diabetologia · doi:10.1007/s00125-006-0583-y · Cited by 4 · see citing works
Self-citationFinally, after 56 years of type 1 diabetes: a regimen that works
Bell, D. S. H. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1472509 · Cited by 3 · see citing works
Self-citationInsulin glargine: a basal insulin for the management of diabetes
Lansang, C. M., & Kennedy, L. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.5.573 · Cited by 3 · see citing works
Nuevos abordajes terapéuticos de la diabetes mellitus tipo 1
Acosta, D. (2004) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(04)74617-3 · Cited by 2 · see citing works
Insulin, glucagon, and oral hypoglycemic drugs
Krans, H. M. J. (2005) · Side effects of drugs annual · doi:10.1016/s0378-6080(05)80464-7 · Cited by 1 · see citing works
Ohira, M., Saiki, A., Nagumo, A., Imamura, H., Kawana, H., Endo, K., Murano, T., Shirai, K., & Tatsuno, I. (2015) · International Journal of Medicine and Pharmacy · doi:10.15640/ijmp.v3n2a2 · Cited by 1 · see citing works
Injectable Systems for Long-Lasting Insulin Therapy
Niloy, K. K. (2019) · doi:10.21007/etd.cghs.2019.0479 · Cited by 1 · see citing works
Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes
Meneghini, L. (2008) · Therapy · doi:10.2217/14750708.5.4.513
Dąbrowski, M. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12427
Sugiyama, Y., Ikemura, M., Okusada, S., Iwakura, T., & Hashida, T. (2016) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.42.562
Degludek: napjaink ideális bázisinzulinja?
Gerő, L. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.5
Albareda, M., Lara, M., Martín‐Baranera, M., Barnés, R., & Vila, L. (2020) · Practical Diabetes · doi:10.1002/pdi.2274
Chubb, B., Evans, M., Wolden, M. L., Christensen, T., & Gundgaard, J. (2013) · Value in Health · doi:10.1016/j.jval.2013.08.685
Kabakov, A., & Merker, A. (2021) · Journal of Pharmacy Technology · doi:10.1177/87551225211055700
INSULINS AND OTHER HYPOGLYCEMIC DRUGS
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53271-8.50008-9
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00897-0
- Authors
- Albright, E. S., Desmond, R., & Bell, D. S. H.
- Affiliations
- University of Alabama at Birmingham (US)
- From the Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
- ORCID
- Bell, David S.H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2004-02-01
- Volume
- 27
- Issue
- 2
- Pages
- 632-633
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1983639156
- Cited by
- 75
- References
- 3
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 3 · 2013: 4 · 2012: 3
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, insulin glargine, NPH insulin, multiple daily insulin injections, nocturnal hypoglycemia, glycemic control, HbA1c, insulin lispro, insulin aspart, fasting blood glucose, long-acting insulin
- MeSH terms
- Insulin Glargine, Blood Glucose, Diabetes Mellitus, Type 1, Drug Administration Schedule, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Reproducibility of Results, Treatment Outcome, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
